Evaluating the Maintenance of Efficacy and Tolerability of Transitioning from IV Anti-CD20 Therapy to Ublituximab: ENHANCE Study Interim Data

site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
Drug Category : Array
Conference Category : Array
Lead Author : Singer B, et al.
Published Date : 29/02/2024
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2024/02/P109_Singer.pdf
Download Text :
Popup Confirmation? :
astra-migrate-meta-layouts : set
Scroll to Top